CYP46A1 SNP: A Drug Target for Personalized Medicine (G10858)

Target Name: CYP46A1

NCBI ID: G10858

CYP46A1

CYP46A1 SNP: A Drug Target for Personalized Medicine

CYP46A1 (CP46), a single-nucleotide polymorphism (SNP) in the C-pyruvate synthase gene (CYP46), is a drug target and a biomarker that has been extensively studied in the context of various diseases, including cancer, cardiovascular diseases, and neurological disorders.

The CYP46 gene encodes a protein that is involved in the final step of the citric acid cycle, also known as the Krebs cycle or tricarboxylic acid (TCA) cycle, a critical pathway for energy metabolism in eukaryotic cells. The CYP46 protein is a key enzyme in the synthesis of aromatic amino acids, such as tryptophan and indole, which are involved in cell signaling, DNA replication, and other essential biological processes.

The CYP46 gene has four exons, and the most studied of them is the A allele, which is associated with the majority of individuals worldwide. The C-pyruvate synthase gene is a key regulator of various cellular processes, including cell growth, metabolism, and stress responses. The CYP46A1 SNP is a polymorphic variant of the A allele, which has been found to be associated with various human diseases.

One of the most significant studies surrounding the CYP46A1 SNP was the potential association between the A allele and the risk of developing cardiovascular disease. A study by the University of California, San Francisco (UCSF) and the University of California, Los Angeles (UCLA) found that individuals with the A allele had a significantly higher risk of developing cardiovascular disease, including heart attack, compared to those without the allele.

This finding has important implications for the development of personalized medicine and therapies that target this particular genetic variation. Researchers are now exploring the use of drugs that target the CYP46A1 SNP to prevent or treat cardiovascular disease in individuals with this genetic variation.

In addition to its association with cardiovascular disease, the CYP46A1 SNP has also been found to be associated with the risk of other diseases, including cancer and neurological disorders. For example, a study by the University of California, San Francisco found that individuals with the A allele had an increased risk of developing breast cancer, compared to those without the allele.

The implications of these findings are significant for the development of new therapies and treatments that target the CYP46A1 SNP. Researchers are now exploring the use of drugs that target this genetic variation to prevent or treat a range of diseases, including cancer, cardiovascular disease, and neurological disorders.

In conclusion, the CYP46A1 SNP is a drug target and biomarker that has been extensively studied in the context of various diseases. Its association with the risk of cardiovascular disease and other conditions makes it an important target for the development of new therapies and treatments. Further research is needed to fully understand the implications of this genetic variation and to develop effective therapies that target it.

Protein Name: Cytochrome P450 Family 46 Subfamily A Member 1

Functions: P450 monooxygenase that plays a major role in cholesterol homeostasis in the brain. Primarily catalyzes the hydroxylation (with S stereochemistry) at C-24 of cholesterol side chain, triggering cholesterol diffusion out of neurons and its further degradation (PubMed:10377398, PubMed:14640697, PubMed:25017465, PubMed:18621681). By promoting constant cholesterol elimination in neurons, may activate the mevalonate pathway and coordinate the synthesis of new cholesterol and nonsterol isoprenoids involved in synaptic activity and learning (By similarity). Further hydroxylates cholesterol derivatives and hormone steroids on both the ring and side chain of these molecules, converting them into active oxysterols involved in lipid signaling and biosynthesis (PubMed:12077124, PubMed:14640697, PubMed:28190002). Acts as an epoxidase converting cholesta-5,24-dien-3beta-ol/desmosterol into (24S),25-epoxycholesterol, an abundant lipid ligand of nuclear NR1H2 and NR1H3 receptors shown to promote neurogenesis in developing brain (PubMed:25017465). May also catalyze the oxidative metabolism of xenobiotics, such as clotrimazole (PubMed:20667828)

The "CYP46A1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CYP46A1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets